428 related articles for article (PubMed ID: 15761110)
1. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
2. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
Xanthou G; Williams TJ; Pease JE
Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
[TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
[TBL] [Abstract][Full Text] [Related]
5. Alpha-chemokine receptors CXCR1-3 and their ligands in idiopathic inflammatory myopathies.
De Paepe B; De Keyzer K; Martin JJ; De Bleecker JL
Acta Neuropathol; 2005 Jun; 109(6):576-82. PubMed ID: 15937690
[TBL] [Abstract][Full Text] [Related]
6. CXCR3-binding chemokines in multiple myeloma.
Pellegrino A; Antonaci F; Russo F; Merchionne F; Ribatti D; Vacca A; Dammacco F
Cancer Lett; 2004 Apr; 207(2):221-7. PubMed ID: 15072832
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
[TBL] [Abstract][Full Text] [Related]
8. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
Müller M; Carter S; Hofer MJ; Campbell IL
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
[TBL] [Abstract][Full Text] [Related]
9. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
10. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.
Watts AO; Scholten DJ; Heitman LH; Vischer HF; Leurs R
Biochem Biophys Res Commun; 2012 Mar; 419(2):412-8. PubMed ID: 22349504
[TBL] [Abstract][Full Text] [Related]
11. Optic neuritis: chemokine receptor CXCR3 and its ligands.
Sørensen TL; Roed H; Sellebjerg F
Br J Ophthalmol; 2004 Sep; 88(9):1146-8. PubMed ID: 15317705
[TBL] [Abstract][Full Text] [Related]
12. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
Stanford MM; Issekutz TB
J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
[TBL] [Abstract][Full Text] [Related]
13. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T; Costantini S; Colonna G
Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists.
Storelli S; Verzijl D; Al-Badie J; Elders N; Bosch L; Timmerman H; Smit MJ; De Esch IJ; Leurs R
Arch Pharm (Weinheim); 2007 Jun; 340(6):281-91. PubMed ID: 17562560
[TBL] [Abstract][Full Text] [Related]
15. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.
Segerer S; Banas B; Wörnle M; Schmid H; Cohen CD; Kretzler M; Mack M; Kiss E; Nelson PJ; Schlöndorff D; Gröne HJ
Am J Pathol; 2004 Feb; 164(2):635-49. PubMed ID: 14742268
[TBL] [Abstract][Full Text] [Related]
16. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
17. Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries.
Stroke IL; Cole AG; Simhadri S; Brescia MR; Desai M; Zhang JJ; Merritt JR; Appell KC; Henderson I; Webb ML
Biochem Biophys Res Commun; 2006 Oct; 349(1):221-8. PubMed ID: 16930533
[TBL] [Abstract][Full Text] [Related]
18. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes.
Kawada K; Sonoshita M; Sakashita H; Takabayashi A; Yamaoka Y; Manabe T; Inaba K; Minato N; Oshima M; Taketo MM
Cancer Res; 2004 Jun; 64(11):4010-7. PubMed ID: 15173015
[TBL] [Abstract][Full Text] [Related]
19. Identification of overlapping but differential binding sites for the high-affinity CXCR3 antagonists NBI-74330 and VUF11211.
Scholten DJ; Roumen L; Wijtmans M; Verkade-Vreeker MC; Custers H; Lai M; de Hooge D; Canals M; de Esch IJ; Smit MJ; de Graaf C; Leurs R
Mol Pharmacol; 2014 Jan; 85(1):116-26. PubMed ID: 24174496
[TBL] [Abstract][Full Text] [Related]
20. Cellular characteristics of neuroblastoma cells: regulation by the ELR--CXC chemokine CXCL10 and expression of a CXCR3-like receptor.
Goldberg-Bittman L; Sagi-Assif O; Meshel T; Nevo I; Levy-Nissenbaum O; Yron I; Witz IP; Ben-Baruch A
Cytokine; 2005 Feb; 29(3):105-17. PubMed ID: 15613278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
